French production facilities latest to be upgraded by Novo Nordisk

25 April 2016

Danish diabetes giant Novo Nordisk (NOV: N) is to invest more than 100 million euros ($112.5 million) in production facilities at its site in northern France.

The expansions at the site are part of Novo Nordisk’s upscaling of its production lines on both sides of the Atlantic to meet the increasing worldwide demand for its diabetes medicines.

Last month work started on a new $1.8 billion facility in Clayton, North Carolina, and the company has also invested in improvements to its sites in Denmark.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK